Novo Nordisk settles Prandin antitrust suit for $19M; Generics maker Oxford Pharma plots new U.S. facility;

@FiercePharma: Ranbaxy fights FDA for killing its approval to make generic Nexium. FiercePharmaManufacturing story | Follow @FiercePharma

@CarlyHFierce: AirFluSal Forspiro won approval in my two favorite countries, Ireland & Czech Republic, which is inconsequential to me but fun nonetheless. | Follow @CarlyHFierce

> Novo Nordisk ($NVO) agreed to pay $19 million to settle a potential class-action suit in the U.S., which claimed the company used "sham" patent litigation to keep a hold on its market for the diabetes drug Prandin. Report

> A generics start-up based in Oxford, England, Oxford Pharmaceuticals, plans to set up a $29 million U.S. facility in Birmingham, AL, that will eventually employ 200 people. Report

> As Allergan's stock rises at the prospect of an Actavis buyout, that offer is growing in value. Report

> Cipla Chairman Yusuf Hamied is grooming his niece and nephew as potential successors to the Indian company's top executives. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Brain tumor treatment device gets early trial halt for efficacy as a combo with chemo. Story | Follow @FierceMedDev

@EmilyWFierce: Shaq is back for $SNY's latest marketing campaign. Release | Follow @EmilyWFierce

> St. Jude's CardioMEMS could help hospitals avoid Affordable Care Act readmission penalties. More

> Baird Capital closes $185M technology, healthcare fund. Item

> Alfred Mann's Second Sight prices $32M IPO for 'bionic eye.' Story

Biotech News

@FierceBiotech: Agios offers another glimpse of 'exciting' early data for a leukemia drug. Report | Follow @FierceBiotech

@JohnCFierce: Lots of discussion about this one -- Average cost of drug R&D? Try $2.9B on for size. Editor's Corner | Follow @JohnCFierce

@DamianFierce: Knight Therapeutics found a buyer for its FDA priority review voucher, selling it to $GILD for $125M. Release | Follow @DamianFierce

> Sanofi's shortlist of CEO candidates so far has a distinct French accent. Item

> Shire orders 500 staffers to move to Boston-area biotech 'Mecca.' Report

> Bind heralds hope for its nanotech cancer drug after mixed Phase II. Story

> Go-go execs at Gilead nab an FDA priority review voucher for $125M. News

Drug Delivery News

> Cynapsus releases clinical trial data about its sublingual thin-film strip for Parkinson's. Item

> Catalent buys particle engineering outfit Micron Technologies. News

> RNAi masking technique allows more efficient delivery. Story

> Medical marijuana company licenses RapidMist device for buccal delivery. Report

> NSF funds further research into only FDA-cleared catheter for rectal delivery. Article

Diagnostics News

> Precision Therapeutics ropes in $60M for corporate overhaul. More

> Cepheid snags $3.3M to roll out rapid Ebola test. Report

> Roche nabs FDA clearance for quick strep test. News

> Illumina, Sequenta partner up on next-gen cancer diagnostic. Article

> Enterome teams up with AbbVie to create molecular Dx for Crohn's disease. Item

Pharma Marketing News

> Payers' hep C delay tactics work: Coverage hurdles may be dampening Harvoni script growth. Article

> How to prep for a 'megablockbuster' launch? Novartis lines up cost-savings data. Report

> Valeant and Allergan's wining-and-dining shows docs still hold the script reins. More

> Painkiller marketing secrets? Check Chicago's unredacted suit against Endo, Purdue, Cephalon, et al. Story

> Sanofi tags newly OK'd MS drug Lemtrada at $158K, ready to tout head-to-head Rebif data. Article

And Finally... Organized crime in Ireland is moving into the counterfeit pharmaceuticals business. Report